[
  {
      "Company": "Javelin Biotech",
      "Model": "Liver Tissue Chip (LTC)",
      "Organs/Tissues": "Human 3D liver tissue (primary hepatocytes ± non-parenchymal cells)",
      "Physiological/Pathological": "Primarily healthy liver function (drug metabolism, clearance). Can model DILI or chronic toxicity",
      "Cell Source": "Qualified primary human hepatocytes (pooled donors) or iPSC-derived; optional Kupffer/stellate cells",
      "Multiple Cell Types": "Yes if co-culturing hepatocytes + stellate or Kupffer (immune) cells",
      "Stromal Cells": "Yes, stellate or endothelial support if desired",
      "Tissue-resident Immune": "Yes if Kupffer cells included",
      "Circulating Immune": "No, single liver compartment, no immune circulation",
      "Crosstalk (Multi-tissue)": "Not in single LTC; multi-organ system in development",
      "Air-Liquid Interface": "No (fully perfused 3D culture)",
      "Extracellular Matrix": "Yes, collagen or proprietary matrix for 3D hepatic arrangement",
      "3D Scaffold": "Yes, 3D hepatocyte aggregates or layered structure in microfluidic chip",
      "Notable Features": "Long-term stable hepatocyte function (2+ weeks), recirculating flow, minimal drug absorption, digital twin software",
      "Plate/Format (Throughput)": "Individual perfused chips in a small controller; up to ~24 chips in parallel",
      "Max Culture Duration": "≥15 days stable hepatic function (albumin, CYP activity)",
      "Readouts - Live Imaging": "Yes, transparent chip for microscopy of cells (viability, morphology)",
      "Readouts - Supernatant Sampling": "Yes, recirculating media sampling for drug/metabolite kinetics",
      "Readouts - Cell Retrieval": "Yes, end-of-run cell harvest for gene expression or enzyme assays",
      "Readouts - Whole Tissue": "Yes, fix entire 3D structure in chip or remove for histology",
      "Readouts - TEER": "No (not a barrier model)",
      "Readouts - MEA": "No",
      "Readouts - Integrated Biosensors": "No embedded sensors; use external sampling + software analytics",
      "Dead Volume": "Low (~mL scale recirculating volume), minimal drug adsorption",
      "Perfused": "Yes, gentle continuous flow in closed-loop microreactor",
      "Gas Mix Controlled": "Incubator environment (5% CO₂, 37°C)",
      "Real-time Microenvironment Control": "Flow & dosing schedules set by user, repeated drug exposures feasible",
      "model_availability": "Commercially available product + cell kit, also service/collaboration"
    },
    {
      "Company": "Javelin Biotech",
      "Model": "Multi-organ ADME Platform (in development)",
      "Organs/Tissues": "Liver, kidney, intestine, etc. interconnected by microfluidic perfusion",
      "Physiological/Pathological": "Whole-body PK modeling (healthy baseline), can incorporate disease variations",
      "Cell Source": "Human primary or iPSC-derived cells for each organ (hepato-, nephro-, intestinal epithelium)",
      "Multiple Cell Types": "Yes across organs; each organ can have multiple relevant cell types",
      "Stromal Cells": "Optional in each organ module (stellate in liver, fibroblasts in gut, etc.)",
      "Tissue-resident Immune": "Possible but not standard; main focus is ADME organs",
      "Circulating Immune": "No integrated immune circulation by default",
      "Crosstalk (Multi-tissue)": "Yes, fluidic linking simulates blood flow among organs",
      "Air-Liquid Interface": "Not typically, these are fully fluid compartments (unless lung is added eventually)",
      "Extracellular Matrix": "Yes in each organ module (collagen, Matrigel for 3D culture)",
      "3D Scaffold": "Yes, 3D organ modules under perfusion",
      "Notable Features": "Systemic ADME approach, recirculation of drug & metabolites across organ compartments, synergy with digital PBPK models",
      "Plate/Format (Throughput)": "Prototype multi-chamber system, low throughput (~1–4 multi-organ sets in parallel)",
      "Max Culture Duration": "Days–weeks per organ, aiming for stable function",
      "Readouts - Live Imaging": "Possible if modules are transparent, not the main focus",
      "Readouts - Supernatant Sampling": "Yes, measure drug levels/metabolites in each organ’s outflow",
      "Readouts - Cell Retrieval": "Yes at endpoint from each organ compartment",
      "Readouts - Whole Tissue": "Yes, fix each organ module for histology",
      "Readouts - TEER": "Possible for intestinal barrier module, but not finalized",
      "Readouts - MEA": "No current plan",
      "Readouts - Integrated Biosensors": "No built-in sensors, rely on sampling for PK data",
      "Dead Volume": "Minimized microfluidic linking to replicate blood volumes",
      "Perfused": "Yes, continuous recirculation among organ chambers",
      "Gas Mix Controlled": "Incubator environment for all modules",
      "Real-time Microenvironment Control": "Potential to modulate flow rates & drug dosing schedules automatically",
      "model_availability": "In co-development with Pfizer, not yet commercially sold"
  }
]
